Get the Stockscreener App
0.5676
4.88%
-0.0291
Moleculin Biotech Inc stock is traded at $0.5676, with a volume of 1.94M.
It is down -4.88% in the last 24 hours and down -26.82% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$0.5967
Open:
$0.6
24h Volume:
1.94M
Relative Volume:
0.39
Market Cap:
$17.19M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0371
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
-16.84%
1M Performance:
-26.82%
6M Performance:
-55.66%
1Y Performance:
-76.55%
1-Day Range:
$0.5565
$0.60
1-Week Range:
$0.54
$0.689
52-Week Range:
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.5676 | 18.34M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin Biotech Releases New Corporate Presentation - TipRanks
Statistical indicators supporting Moleculin Biotech Inc.’s strengthJuly 2025 Trends & Growth Oriented Trade Recommendations - Newser
Using Bollinger Bands to evaluate Moleculin Biotech Inc.Earnings Overview Summary & Community Consensus Picks - Newser
Will Moleculin Biotech Inc. stock recover after recent drop2025 Market Overview & Smart Allocation Stock Reports - Newser
Custom watchlist performance reports with Moleculin Biotech Inc.July 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Using RSI to spot recovery in Moleculin Biotech Inc.July 2025 Earnings & Trade Opportunity Analysis Reports - Newser
What’s the recovery path for long term holders of Moleculin Biotech Inc.Recession Risk & Safe Entry Point Identification - Newser
Has Moleculin Biotech Inc. Stock Ever Crashed Historical Volatility ReviewShare Buyback & Consistent Income Trade Recommendations - Newser
Is Moleculin Biotech Inc. forming a breakout patternJuly 2025 Drop Watch & Real-Time Market Trend Scan - thegnnews.com
HC Wainwright Has Positive Estimate for MBRX Q3 Earnings - Defense World
How to use Fibonacci retracement on Moleculin Biotech Inc.Market Risk Summary & Safe Entry Trade Signal Reports - Newser
Using AI based signals to follow Moleculin Biotech Inc.2025 Top Decliners & Long-Term Safe Investment Plans - Newser
What’s the outlook for Moleculin Biotech Inc.’s sectorJuly 2025 Opening Moves & Risk Controlled Stock Pick Alerts - thegnnews.com
Applying Elliott Wave Theory to Moleculin Biotech Inc.2025 Institutional Moves & Weekly Breakout Opportunity Watchlist - Newser
Combining price and volume data for Moleculin Biotech Inc.Market Weekly Review & Target Return Focused Picks - Newser
Is Moleculin Biotech Inc. stock bottoming outJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - Newser
Does Moleculin Biotech Inc. fit your quant trading modelJuly 2025 Closing Moves & Free Community Supported Trade Ideas - Newser
Is Moleculin Biotech Inc. stock a buy or sellJuly 2025 Selloffs & Short-Term Trading Opportunity Alerts - thegnnews.com
Webull Corporation shares rise 1.49% premarket after AIM ImmunoTech and Moleculin Biotech to present at Webull Financial Corporate Connect Webinar Series. - AInvest
Moleculin Biotech reports Q2 EPS (49c) vs. ($1.70) last year - MSN
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
Moleculin Biotech Misses Fiscal Q2 EPS - AOL.com
Moleculin Biotech to present at Webull Financial Corporate Connect webinar series - AInvest
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewswire
Late-Stage Cancer Drug Developer Moleculin Showcases Pipeline at Webull Healthcare Event - Stock Titan
Moleculin Biotech Reports Q2 2025 Financial Results - MSN
Moleculin Reports Second Quarter 2025 Financial Results and Highlights - GlobeNewswire
Moleculin Biotech Inc's Q2 2025 EPS Falls Short of Analyst Estimates, Annamycin Program Advances Amid Financial Challenges - AInvest
Moleculin Biotech: A High-Risk, High-Reward Play in Oncology Innovation Amid Capital Constraints - AInvest
Moleculin's Cancer Drug Trial Grows Globally as Critical Data Readout Approaches in 2025 - Stock Titan
Promising Developments in Annamycin Drive Buy Rating for Moleculin Biotech - TipRanks
How liquid is Moleculin Biotech Inc. stockJuly 2025 Final Week & Verified Chart Pattern Signals - newsyoung.net
Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Moleculin Biotech MBRX 2025Q2 Earnings Preview Upside Potential Driven by Strategic Developments - AInvest
Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Grows By 52.0% - Defense World
Heatmap analysis for Moleculin Biotech Inc. and competitorsMomentum Trend Signal Weekly Recap Summary - Newser
Moleculin Biotech shares rise 3.66% premarket after unveiling promising preclinical data for Annamycin. - AInvest
Moleculin Biotech shares fall 5.11% intraday despite promising preclinical data for Annamycin. - AInvest
Moleculin Biotech announces preclinical data of annamycin in liver cancer - TipRanks
Moleculin Biotech Reveals Promising Preclinical Data for Annamycin - TipRanks
Moleculin Biotech Highlights Annamycin's Potential Against Liver Cancers with Promising Preclinical Data - Quiver Quantitative
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment - GlobeNewswire
Revolutionary Cancer Treatment: Moleculin's Annamycin Targets 3 Types of Liver Cancer Without Heart Risks - Stock Titan
Moleculin Biotech shares rise 5.55% intraday after unveiling promising preclinical data for Annamycin. - AInvest
What is Moleculin Biotech Inc. company’s growth strategyMaximize returns with expert trading insights - Jammu Links News
Is Moleculin Biotech Inc. a good long term investmentAchieve unparalleled market performance - Jammu Links News
How does Moleculin Biotech Inc. compare to its industry peersInvest smarter with high-probability setups - Jammu Links News
Is it the right time to buy Moleculin Biotech Inc. stockUnlock real-time trading signals for gains - Jammu Links News
What makes Moleculin Biotech Inc. stock price move sharplyBuild a diversified portfolio for steady profits - Jammu Links News
Moleculin Biotech Releases Corporate Presentation Update - AInvest
What are the latest earnings results for Moleculin Biotech Inc.Capitalize on emerging trends for profits - Jammu Links News
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moleculin Biotech Inc Stock (MBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):